Development and Targeting Efficiency of Irinotecan Engineered Proniosomes

The aim of the study was to develop a proniosomal system for famotidine (FAM), a potent H 2 receptor antagonist that could efficiently deliver entrapped drug over a prolonged period of time. The proniosomal system was formulated by selecting various ratios of Span 60 and cholesterol using a coacervation-phase separation method. The formulated systems were characterised for drug excipient compatibility studies by Fourier transform infrared spectroscopy (FTIR), vesicle size determination by the particle size analyser, % drug encapsulation, drugrelease profiles, field emission scanning electron microscopy (FESEM) for surface morphology, X-ray diffraction (XRD) and vesicular stability at different storage conditions. By using this method, the % drug loading that resulted by the encapsulation of proniosome was found to be 78%À89%. Increase in cholesterol and surfactant concentration increases encapsulation efficiency, but further increment decreases encapsulation. In vitro drug-release studies showed prolonged release of entrapped famotidine. The highest % cumulative drug release was achieved in formulation FAM2 (96%) in 24 hours. The ex vivo data on the release of famotidine from proniosomal formulations have shown significantly increased per cent release and flux in comparison to the same dose of marketed preparation of famotidine. Stability studies were carried out in refrigerated conditions, and higher drug retention was observed. It is evident from this study that proniosomes are a promising prolonged delivery system for famotidine and have reasonably good stability characteristics.

show abstract

“…[14] The obtained low value of polydispersity index of proniosome-derived niosomes indicates a limited variation in particle size ( Figure 7).…”

Section: Discussionmentioning

confidence: 99%

Formulation and optimisation of famotidine proniosomes: anin vitroandex vivostudy

Mokale

Patil

et al. 2015

Journal of Experimental Nanoscience

View full text Add to dashboard Cite

show abstract

“…Stability tests of the F2 formulation indicate that an average increase in drug release (P<0.05) has developed.These results may be due, to some extents in storage, to the phase transition of surfactant and lipid causing vesicle leakage.It can be noticed from the stability data that 4 o C is the most acceptable condition of irinotecanloaded proniosome storage [27].…”

Section: Sem Of (mentioning

confidence: 99%

Irinotecan Engineered Proniosomes: In vitro and In vivo Characterization

Goudanavar¹,

Bantu²,

Fattepur

et al. 2021

JPRI

View full text Add to dashboard Cite

Objective: The focus of this research has been to improve efficacy, decrease tolerance and increase the irinotecan pharmacokinetic profile. Methods: Proniosomesformulated with various surfactants, cholesterol and dicetyl phosphate using the slurry method. A slurry process was used to prepare proniosomes with maltodextrin as the carrier by using surfactants span 20, span 60, tween 20 and tween 80. Results: The preparations were characterized in terms of shape and specific surface area, entrapment efficacy, in vitro release studies, in vivo tissue diffusion and stability testing. The proniosome surface was found to be smoother in nature showing thin and compact layer with skim milk powder. For formulation 2 (73.94±2.8%), the maximum entrapment efficacy was found. Conclusion: The formulation 3 obtained the desired maximum release profile within 24 hours (98.06%). The in vivo tissue distribution studies for the proniosomes reveal that the drug was preferentially targeted to liver followed by the alveolus and lymphatic system.Stability studies have indicated that the most acceptable condition for storage of the formulation 2 was 4o C. Proniosomes provide an acceptable method to the carrier for targeted therapy. These can be held at specific sites and can release the drug for a prolonged period of time.

show abstract